XORTX receives proxy firm backing for share consolidation vote

XORTX Therapeutics Inc. (NASDAQ: XRTX) announced that Institutional Shareholder Services and other independent proxy advisory firms have recommended shareholders vote in favor of a proposed share consolidation at the company's March 24, 2026 shareholder meeting.

ISS stated the stock consolidation should have no direct impact on shareholder value and could enhance the company's long-term growth prospects by broadening financing alternatives. The proxy voting deadline is March 20, 2026, with shareholders of record as of February 20, 2026 eligible to vote.

XORTX's board of directors unanimously recommends shareholders vote for all resolutions at the meeting. The Calgary-based pharmaceutical company focuses on developing treatments for gout and progressive kidney disease.

"We are pleased to receive the news that an independent third-party proxy advisory firm, ISS, has recommended shareholders vote FOR all of the proposed resolutions," said Dr. Allen Davidoff, CEO of XORTX.

The company has three clinically advanced products in development: XRx-026 for gout treatment, XRx-008 for ADPKD, and XRx-101 for acute kidney and organ injury associated with respiratory virus infections. XORTX is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy.

Shareholders requiring voting assistance can contact Laurel Hill Advisory Group at 1-877-452-7184 for North America or 1-416-304-0211 for international calls.

You May Also Be Interested In

• Nutrien warns shareholders about below-market mini-tender offer
• Pop Culture Group prices $8 million direct offering at $0.15 per share
• XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange